CYCLO THERAPEUTICS INC (CYTH) Stock Price, Quote, News and Overview
NASDAQ:CYTH - Nasdaq - US23254X2018 - Common Stock - Currency: USD
CYTH Quote, Performance and Key Statistics
CYCLO THERAPEUTICS INC
NASDAQ:CYTH (2/10/2025, 8:00:01 PM)
After market: 0.9188 -0.01 (-0.99%)0.928
-0.26 (-22.02%)
The current stock price of CYTH is 0.928 USD. In the past month the price increased by 48.96%. In the past year, price decreased by -47.27%.
CYTH Latest News and Analysis
Which stocks are experiencing notable movement on Monday?
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Monday's pre-market session: top gainers and losers
Discover the top movers in Monday's pre-market session and stay informed about market dynamics.
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)
Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, FLIC, ARCH, CYTH on Behalf of Shareholders
CYTH Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.81 | 336.36B | ||
| AMGN | AMGEN INC | 14.87 | 158.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 921.51 | 121.03B | ||
| GILD | GILEAD SCIENCES INC | 21.55 | 118.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.13 | 75.86B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.66B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.35B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.63B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.41B | ||
| NTRA | NATERA INC | N/A | 22.73B | ||
| BIIB | BIOGEN INC | 8.73 | 20.77B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.18 | 15.43B |
Related stock screener links
About CYTH
Company Profile
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 8 full-time employees. The company went IPO on 2004-02-27. The firm is focused on developing transformative therapies for rare and neurological diseases with limited treatment options. The Company’s Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin. The company is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick Disease Type C (NPC) disease. NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. The firm is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).
Company Info
CYCLO THERAPEUTICS INC
6714 Nw 16Th Street, Suite B
Gainesville Florida FLORIDA 32653 US
CEO: N. Scott Fine
Employees: 8
Company Website: https://www.cyclotherapeutics.com/
Investor Relations: http://cyclotherapeutics.com/overview/
Phone: 13864188060
CYTH FAQ
What is the stock price of CYTH?
The current stock price of CYTH is 0.928 USD.
What is the symbol for CYCLO THERAPEUTICS INC stock?
The exchange symbol of CYCLO THERAPEUTICS INC is CYTH and it is listed on the Nasdaq exchange.
On which exchange is CYTH stock listed?
CYTH stock is listed on the Nasdaq exchange.
Is CYTH a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for CYTH, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of CYTH.
Does CYTH stock pay dividends?
CYTH does not pay a dividend.
What is the Price/Earnings (PE) ratio of CYTH?
CYTH does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.92).
What is the Short Interest ratio of CYTH stock?
The outstanding short interest for CYTH is 0.64% of its float.
CYTH Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CYTH. When comparing the yearly performance of all stocks, CYTH is a bad performer in the overall market: 76.41% of all stocks are doing better.
CYTH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CYTH. CYTH has a bad profitability rating. Also its financial health evaluation is rather negative.
CYTH Financial Highlights
Over the last trailing twelve months CYTH reported a non-GAAP Earnings per Share(EPS) of -0.92. The EPS increased by 44.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -472.02% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CYTH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to CYTH. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 56.84% and a revenue growth -41.47% for CYTH